Navigation Links
FDA approves GlaxoSmithKline's VOTRIENT(TM) for advanced renal cell cancer
Date:10/19/2009

PHILADELPHIA, Oct. 19 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved VOTRIENT(TM) (pazopanib) to treat patients with advanced renal cell carcinoma (RCC), a form of kidney cancer. Approximately 57,700 people in the U.S. will be diagnosed with kidney cancer this year, and 13,000 people will die from this disease.

"RCC is the most common malignancy of the kidney and is highly resistant to chemotherapy," said Paolo Paoletti, MD, Senior Vice President, GlaxoSmithKline Oncology R&D Unit. "While treatment has improved in the past few years with the introduction of targeted therapies, advanced RCC remains a challenging disease. VOTRIENT will join existing targeted therapies to provide physicians with a new oral treatment option to their patients with advanced renal cell cancer."

VOTRIENT, a once-daily, oral medication, is an angiogenesis inhibitor which may help prevent the growth of new blood vessels, thereby blocking the growth of kidney cancer tumors that need blood vessels to survive.

The approval of VOTRIENT was supported by a unanimous decision by the FDA's Oncology Drugs Advisory Committee (ODAC) that the benefit-to-risk profile for VOTRIENT is acceptable for patients with advanced kidney cancer. The ODAC reviewed data from a Phase III clinical trial showing that VOTRIENT reduced the risk of tumor progression or death by 54 percent compared to placebo, regardless of prior treatment.

In this Phase III trial, the overall median PFS was 9.2 months with pazopanib and 4.2 months with placebo. Treatment-naive patients who received VOTRIENT experienced 11.1 months of median progression-free survival (PFS) versus 2.8 months with placebo. Additionally, patients who had previously received cytokine-based treatment achieved 7.4 mo
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Seasonal Influenza Vaccine Fluarix for Pediatric Use
2. FDA Approves New Treatment for Advanced Form of Kidney Cancer
3. FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
4. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
5. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
6. Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material
7. FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
10. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
11. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Asterias Biotherapeutics, Inc. (NYSE MKT: ... of regenerative medicine, today announced that the abstract describing ... from the Phase 2 clinical trial of the Company,s ... selected for an oral presentation at the 2015 American ... held in Chicago, Illinois May ...
(Date:4/20/2015)... 2015  Following is the daily "Profile America" feature ... MEDICINE Profile America — ... insulin —became available for general use this month in ... from diabetes. Insulin is a hormone produced by the ... in the human body. It was first isolated the ...
(Date:4/20/2015)... Ireland , April 20, 2015 ... that Charles M. Mayr , Chief Communications ... due to health reasons.  In conjunction with Mayr,s ... will assume the role of Chief Communications Officer, ... Kelly served as Senior Vice President, Chief Communications ...
Breaking Medicine Technology:Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting 2Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting 3U.S. Census Bureau Daily Feature for April 21 2Actavis Announces Retirement of Charles M. Mayr 2Actavis Announces Retirement of Charles M. Mayr 3
... CUPERTINO, Calif., May 3, 2012 DURECT Corporation ... issuance of four patents by the United States ... technology.  These patents provide additional intellectual property protection ... ORADUR-based opioids until at least 2025. REMOXY, based ...
... New York, May 3, 2012 New ... Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 ... tables and figures. Worldwide markets are poised to achieve significant ... clinical care delivery to patients with chronic disease, decreasing hospitalizations ...
Cached Medicine Technology:DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology 2DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology 3DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology 4ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report 2ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report 3ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report 4ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report 5ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report 6ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report 7ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report 8
(Date:4/21/2015)... 2015 Carinsurancesavings.biz has released a new blog ... surveillance and explaining the impact on a uto insurance ... and supervised may be eligible for advantageous auto insurance discounts. ... simple and efficient way. This will also help them get ... simple way. , Finding low cost coverage is no longer ...
(Date:4/21/2015)... 2015 Optimity Advisors ( Optimity), ... firm that helps clients in complex industries navigate ... the Association of Community Affiliated Plans ... represents 58 local, not-for-profit, community-affiliated Safety Net Health ... people primarily enrolled in public or state-sponsored coverage ...
(Date:4/21/2015)... CO (PRWEB) April 21, 2015 ... Management , a new knowledge management solution that ... and publishing of policies and procedures. With Quark ... create reusable content that is easy to save, ... is susceptible to risk and compliance issues. Examples ...
(Date:4/21/2015)... When a bandage sticks to an injury ... to solve this problem two inventors from Festus, Mo., ... bandage helps a cut, burn, abrasion or wound heal ... exposure. The bandage is easy to use, versatile and ... submitted to the St. Louis office of InventHelp. It ...
(Date:4/21/2015)... Ill. (PRWEB) April 21, 2015 The ... the late cosmetic dermatologist Fredric S. Brandt, M.D., by ... Dr. Brandt, an ASDS member since 1982, died earlier ... The funds are designed to provide opportunities for ASDS ... field of cosmetic dermatology that Dr. Brandt held so ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Quotes Offer Excellent Security for A Car 2Health News:Optimity Advisors Named Preferred Vendor by the Association of Community Affiliated Plans (ACAP) 2Health News:Quark Software Inc. Introduces Procedure Management Solution for Global 2000 2Health News:Quark Software Inc. Introduces Procedure Management Solution for Global 2000 3Health News:ASDS honors the legacy of Dr. Fredric Brandt 2Health News:ASDS honors the legacy of Dr. Fredric Brandt 3Health News:ASDS honors the legacy of Dr. Fredric Brandt 4
... HealthDay Reporter , TUESDAY, May 1 (HealthDay News) -- ... research that seeks to determine if medical treatments and prevention ... poor quality. Studies of cancer treatments, in particular, often ... analysis found. Meanwhile, a full 7 percent of the studies ...
... CT for detecting superior semicircular canal dehiscence or the so called ... inner ear bone that can cause dizziness and hearing loss) and ... The study, conducted in Bruges, Belgium, included 21 patients who had ... their right and left temporal bones, said David Volders, MD, one ...
... have gained insight into the mechanism by which a ... of Alzheimer,s disease (AD) and other neurodegenerative disorders. This ... Journal of Biological Chemistry, may provide the ... from damaging brain circuits involved in cognitive function. ...
... in sarcomas, researchers at Moffitt Cancer Center used state-of-the-art ... enzymes that act as "on" or "off" switches important ... identified, the researchers said, could act as "drivers" for ... relatively rare forms of cancer. In contrast to carcinomas, ...
... MAYWOOD, Ill. -- There,s a high rate of depression ... for the disease includes a drug, interferon, that can ... the complexities of diagnosing and managing depression before and ... Rao of Loyola University Medical Center is a co-author ...
... a significantly greater number of highly educated women in their ... a dramatic turnaround from recent history. Among college-educated women, ... had no children, according to the new analysis of U.S. ... and 2008. "We may be seeing the beginning of ...
Cached Medicine News:Health News:Analysis Finds Clinical Trials Often Small, of Poor Quality 2Health News:Analysis Finds Clinical Trials Often Small, of Poor Quality 3Health News:Researchers gain better understanding of mechanism behind tau spreading in the brain 2Health News:Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival 2Health News:Hepatitis C drug can cause depression 2Health News:Greater numbers of highly educated women are having children, bucking recent history 2Health News:Greater numbers of highly educated women are having children, bucking recent history 3
... 1300 C is ideal for evaluating a wide ... parts of the body. Often referred to at ... magnetocardiography, gastrointestinal tract, fetal, spinal cord and peripheral ... C, with its 67 detector coils, covers a ...
... table configurations designed for a wide range ... capture 17 X 17 X-ray images from ... system includes a Bucky table, upright tilting ... suspended multi-positioning unit. Versatile and economical, the ...
... synthetic bone filler tailored for slow ... and Hydroxyapatite (HAP), its composition mimics ... the chemistry and microstructure of Bi-Ostetic ... provides optimal osteo-conduction. The spongy Bi-Ostetic ...
The TB Lead is a high quality bipolar intracardiac lead for cost effective temporary pacing and electrophysiology studies. The TB lead is available in sizes ranging from 4F to 6F and comes in either ...
Medicine Products: